Clinical Trial Update: Dose-finding Study of LIK066 Compared With Placebo or Sitagliptin to Evaluate Change in HbA1c in Patients With Diabetes [Phase 2]

View source ↗

Summary

Phase 2 dose-finding trial of LIK066 in Type 2 diabetes was withdrawn, with the study comparing LIK066 to placebo or sitagliptin to assess HbA1c change.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Type 2 Diabetes Mellitus

Drugs mentioned

• LIK066 (LIK066)
• Sitagliptin (sitagliptin)

Snippet

Sponsor: Novartis Pharmaceuticals | Conditions: Type 2 Diabetes Mellitus | Phase 2 | Status: WITHDRAWN